ATC Group: N07AA30 Ambenonium

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N07AA30 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N07 Other nervous system drugs
3 N07A Parasympathomimetics
4 N07AA Anticholinesterases
5 N07AA30 Ambenonium

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 60 mg

Active ingredients in N07AA30

Active Ingredient Description

Ambenonium (as ambenonium dichloride) is a cholinesterase inhibitor used in the management of myasthenia gravis. Ambenonium exerts its actions against myasthenia gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine.

Medicines in this ATC group

France (FR)

Japan (JP)

Poland (PL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.